133 related articles for article (PubMed ID: 32305990)
1. Influence of Hypertension on the Survival of Non-Small Cell Lung Cancer Patients with Type 2 Diabetes Mellitus.
Zeng X; Zeng D; Cheng J; Xu C; Sun C; Long H; Zhu B
Med Sci Monit; 2020 Apr; 26():e921676. PubMed ID: 32305990
[TBL] [Abstract][Full Text] [Related]
2. Poor glycemic control might compromise the efficacy of chemotherapy in non-small cell lung cancer patients with diabetes mellitus.
Zeng X; Xu C; Cheng J; Sun C; Wang Z; Gong Z; Long H; Zhu B
Cancer Med; 2020 Feb; 9(3):902-911. PubMed ID: 31830375
[TBL] [Abstract][Full Text] [Related]
3. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
4. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer.
Wang NF; Tang HM; Liu FL; Hong QY
Chin Med J (Engl); 2020 Apr; 133(7):786-791. PubMed ID: 32195672
[TBL] [Abstract][Full Text] [Related]
5. Comorbidities and mortality risk among extensive-stage small-cell lung cancer patients in mainland China: impacts of hypertension, type 2 diabetes mellitus, and chronic hepatitis B virus infection.
Xiu W; Huang Y; Li Y; Yu M; Gong Y
Anticancer Drugs; 2022 Jan; 33(1):80-90. PubMed ID: 34183497
[TBL] [Abstract][Full Text] [Related]
6. [Risks of type 2 diabetes mellitus and impaired glucose regulation among elderly patients with essential hypertension: a 10-years cohort study].
Li YP; Shao YH; Tian H; Fang FS; Sun BR; Xiao J; Pei Y; Yan ST; Han XF; Li CX
Zhonghua Yi Xue Za Zhi; 2012 Jan; 92(2):102-5. PubMed ID: 22490691
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
Chiappori AA; Kolevska T; Spigel DR; Hager S; Rarick M; Gadgeel S; Blais N; Von Pawel J; Hart L; Reck M; Bassett E; Burington B; Schiller JH
Ann Oncol; 2015 Feb; 26(2):354-62. PubMed ID: 25467017
[TBL] [Abstract][Full Text] [Related]
8. Progression from impaired fasting glucose to type 2 diabetes mellitus among Chinese subjects with and without hypertension in a primary care setting.
Fu SN; Luk W; Wong CK; Cheung KL
J Diabetes; 2014 Sep; 6(5):438-46. PubMed ID: 24393475
[TBL] [Abstract][Full Text] [Related]
9. Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Chen H; Yao W; Chu Q; Han R; Wang Y; Sun J; Wang D; Wang Y; Cao M; He Y
Cancer Lett; 2015 Dec; 369(1):97-102. PubMed ID: 26341687
[TBL] [Abstract][Full Text] [Related]
10. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment albumin/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy.
Ying J; Zhou D; Gu T; Huang J; Liu H
BMC Cancer; 2019 Mar; 19(1):288. PubMed ID: 30925910
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
13. Is diabetes mellitus a negative prognostic factor for the treatment of advanced non-small-cell lung cancer?
Inal A; Kaplan MA; Kucukoner M; Urakcı Z; Kılınc F; Isıkdogan A
Rev Port Pneumol; 2014; 20(2):62-8. PubMed ID: 24210228
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Nivolumab versus Docetaxel as Second-Line Treatment in Non-Small Cell Lung Cancer Patients in Clinical Practice.
Calpe-Armero P; Ferriols-Lisart R; Ferriols-Lisart F; Pérez-Pitarch A
Chemotherapy; 2017; 62(6):374-380. PubMed ID: 29045938
[TBL] [Abstract][Full Text] [Related]
15. A Clinical Prognostic Score to Predict Survival of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy: A Retrospective Analysis.
Gong J; Xu L; Li Z; Hu X; Liu J; Teng Y; Jin B; Zhao M; Shi J; Guo T; Shi X; Cheng Y; Liu Y; Qu X
Med Sci Monit; 2018 Nov; 24():8264-8271. PubMed ID: 30446633
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer.
Zietemann V; Duell T
Lung Cancer; 2011 Jul; 73(1):70-7. PubMed ID: 21095039
[TBL] [Abstract][Full Text] [Related]
17. KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer.
Ardeshir-Larijani F; Bhateja P; Lipka MB; Sharma N; Fu P; Dowlati A
Clin Lung Cancer; 2018 Jul; 19(4):e489-e501. PubMed ID: 29627316
[TBL] [Abstract][Full Text] [Related]
18. [Exploration of the rational therapeutic regimen for advanced lung cancer patients with mild tumor enlargement].
Zhang XL; Wang XY; Zhang CC; Yang J; Yuan XH; Li K
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):775-782. PubMed ID: 29061023
[No Abstract] [Full Text] [Related]
19. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
20. Survival difference in NSCLC and SCLC patients with diabetes mellitus according to the first-line therapy.
Nakazawa K; Kurishima K; Tamura T; Ishikawa H; Satoh H; Hizawa N
Med Oncol; 2013 Mar; 30(1):367. PubMed ID: 23307241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
